Ovarian Cancer Clinical Trials in Eugene, Oregon

4 studies are recruiting for ovarian cancer in Eugene, Oregon right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

    The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Oncology Associates of Oregon, P.C., Eugene, Oregon
    Locations
    192 in total
    Run by
    Incyte Corporation

    See if you can join NCT07214779 on ClinicalTrials.gov

  2. A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

    The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8010), Eugene, Oregon
    Locations
    196 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06824467 on ClinicalTrials.gov

  3. A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

    Ovarian cancer is a lethal disease with an estimated 310,000 new cases and 200,000 deaths experienced worldwide in 2020. The purpose of this study is to assess the adverse events and change in disease activity of mirvetuximab soravtansine with carboplatin, or bevacizumab (Bev), or bev alone in part…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Willamette Valley Cancer Institute and Research Center /ID# 277714, Eugene, Oregon
    Locations
    83 in total
    Run by
    AbbVie

    See if you can join NCT07059845 on ClinicalTrials.gov

  4. Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

    This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    517, Eugene, Oregon
    Locations
    49 in total
    Run by
    Corcept Therapeutics

    See if you can join NCT06906341 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.